Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-04-15

Clinical Trial Update: A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA) [Phase 2]

View source ↗

Summary

Chelsea Therapeutics reports completion of a Phase 2 clinical trial evaluating CH-4051 in patients with rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CH-4051

Snippet

Sponsor: Chelsea Therapeutics | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED